---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-098509"
form_type: "8-K"
ticker: "TCRX"
cik: "0001783328"
company_name: "TScan Therapeutics, Inc."
filed_at: "2024-04-17T23:59:59+00:00"
generated_at: "2026-06-03T21:45:56.003416+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# TScan Therapeutics prices upsized $150M public offering; provides preliminary cash of $162.8M

## Summary
- Pricing of 2,472,581 shares at $7.13/share and pre-funded warrants for 18,577,419 shares at $7.1299/warrant.
- Gross proceeds ~$150.1M; net proceeds ~$144.7M (or ~$165.9M if underwriters exercise overallotment for 3,157,500 additional shares).
- Cash, cash equivalents and marketable securities of $162.8M as of March 31, 2024 (preliminary, unaudited).
- Proceeds expected to fund operations into Q4 2026; use for general corporate purposes.
- Offering expected to close April 19, 2024; Morgan Stanley and TD Cowen joint book-runners.

## SEC filing metadata
- accession: 0001193125-24-098509
- form_type: 8-K
- ticker: TCRX
- cik: 0001783328
- company_name: TScan Therapeutics, Inc.
- filed_at: 2024-04-17T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.01, 2.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1783328/000119312524098509/0001193125-24-098509-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1783328/000119312524098509/d816959d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-098509
- JSON: https://secwatch.observer/filing/0001193125-24-098509.json
- Plain text: https://secwatch.observer/filing/0001193125-24-098509.txt

## Key facts
- Material Agreements
  TScan Therapeutics, Inc. entered into Underwriting Agreement with Morgan Stanley & Co. LLC and TD Securities (USA) LLC valued at $144.7 million (effective 2024-04-16).
  - Action: entry
  - Agreement: underwriting
  - Counterparty: Morgan Stanley & Co. LLC and TD Securities (USA) LLC
  - Value: $144.7 million
  - Effective: 2024-04-16
  source text: On April 16, 2024, TScan Therapeutics, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Morgan Stanley & Co. LLC and TD Securities (USA) LLC, as representatives (the “Representatives”) of the underwriters named therein (the “Underwriters”), pursuant to which the Company agreed to issue and sell an aggregate of (a) 2,472,581 shares (the “Firm Shares”) of its voting common stock, par value $0.0001 per share (the “Voting Common Stock”), at a price to the public of $7.1300 per share, and (b) pre-funded warrants to purchase up to 18,577,419 shares of the Company’s Voting Common Stock (the “Pre-Funded Warrants”), at a price to the public of $7.1299 per warrant with an exercise price of $0.0001 per share (the “Offering”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1783328/000119312524098509/0001193125-24-098509-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.